| Number . | Age . | Gender . | Ki67 . | Biochemistry at Diagnosis . | Hormone Symptoms at Diagnosis . | Secondary Hormone Production . | Time From Diagnosis to Second Hormone . | Time From Second Hormone to Death . | Progression From Second Hormone, mo . | Survival, Months . | Treatment Prior to Conversion . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | M | VIP | VIPoma | Calcitonin | 132 | 20 | Dead, 152 | SSA, Stz + 5FU | ||
| 2 | 75 | F | 12 | PP | 0 | Glucagon, inulin | 90 | 4 | Dead, 94 | Platinum, SSA, Inf, Tmz, Emb, Eve | |
| 3 | 76 | M | 6 | PP | 0 | Insulin, proinsulin | 41 | 18 | Dead, 60 | Tmz, SSA, Stz + 5FU | |
| 4 | 74 | M | 9 | 0 | 0 | Insulin | 18 | 2 | −3 | Dead, 20 | Tmz |
| 5 | 56 | F | Glucagon, proinsulin | Glucagonoma | Insulin | 213 | 20 | Dead, 233 | Strz + 5FU, Tmz, 177Lu-DOTA-octreotate | ||
| 6 | 74 | M | 1 → 40 | 0 | 0 | Insulin, glucagon | 47 | 6 | 0 | Dead, 52 | Stz + 5FU, platinum, |
| 7 | 57 | M | 3 → 1 | 0 | 0 | Glucagon | 12 | 68 | Dead, 81 | ||
| 8 | 56 | F | 10 | PP, proinsulin | 0 | Insulin | 51 | 10 | 0 | Dead, 61 | Stz + Doxo Stz + 5FU, Inf, Im, Tmz |
| 9 | 44 | M | 30 | Gastrin | Gastrinoma | ACTH | 169 | 5 | Dead, 173 | ||
| 10 | 62 | F | 4 | Glucagon, PP, calcitonin, VIP | VIPoma | Insulin | 22 | 13 | 1 | Dead, 46 | Stz + 5FU, Eve |
| 11 | 57 | M | 4 → 17 | 0 | 0 | ACTH | 56 | 19 | 1 | Dead, 76 | Stz + 5FU, Platinum, Tmz + Cap |
| 12 | 44 | M | 3 | VIP | VIPoma | Glucagon, gastrin | 60 | 31 | 0 | Dead, 90 | Stz + 5FU, Tmz |
| 13 | 17 | F | Insulin, pro-insulin, gastrin | Insulinoma | ACTH | 42 | 31 | Dead, 73 | — | ||
| 14 | 49 | M | 0 | 0 | Gastrin | 60 | 31 | Dead, 71 | SSA + Inf, Stz + 5FU, Pac + Doxo, Platinum |
| Number . | Age . | Gender . | Ki67 . | Biochemistry at Diagnosis . | Hormone Symptoms at Diagnosis . | Secondary Hormone Production . | Time From Diagnosis to Second Hormone . | Time From Second Hormone to Death . | Progression From Second Hormone, mo . | Survival, Months . | Treatment Prior to Conversion . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | M | VIP | VIPoma | Calcitonin | 132 | 20 | Dead, 152 | SSA, Stz + 5FU | ||
| 2 | 75 | F | 12 | PP | 0 | Glucagon, inulin | 90 | 4 | Dead, 94 | Platinum, SSA, Inf, Tmz, Emb, Eve | |
| 3 | 76 | M | 6 | PP | 0 | Insulin, proinsulin | 41 | 18 | Dead, 60 | Tmz, SSA, Stz + 5FU | |
| 4 | 74 | M | 9 | 0 | 0 | Insulin | 18 | 2 | −3 | Dead, 20 | Tmz |
| 5 | 56 | F | Glucagon, proinsulin | Glucagonoma | Insulin | 213 | 20 | Dead, 233 | Strz + 5FU, Tmz, 177Lu-DOTA-octreotate | ||
| 6 | 74 | M | 1 → 40 | 0 | 0 | Insulin, glucagon | 47 | 6 | 0 | Dead, 52 | Stz + 5FU, platinum, |
| 7 | 57 | M | 3 → 1 | 0 | 0 | Glucagon | 12 | 68 | Dead, 81 | ||
| 8 | 56 | F | 10 | PP, proinsulin | 0 | Insulin | 51 | 10 | 0 | Dead, 61 | Stz + Doxo Stz + 5FU, Inf, Im, Tmz |
| 9 | 44 | M | 30 | Gastrin | Gastrinoma | ACTH | 169 | 5 | Dead, 173 | ||
| 10 | 62 | F | 4 | Glucagon, PP, calcitonin, VIP | VIPoma | Insulin | 22 | 13 | 1 | Dead, 46 | Stz + 5FU, Eve |
| 11 | 57 | M | 4 → 17 | 0 | 0 | ACTH | 56 | 19 | 1 | Dead, 76 | Stz + 5FU, Platinum, Tmz + Cap |
| 12 | 44 | M | 3 | VIP | VIPoma | Glucagon, gastrin | 60 | 31 | 0 | Dead, 90 | Stz + 5FU, Tmz |
| 13 | 17 | F | Insulin, pro-insulin, gastrin | Insulinoma | ACTH | 42 | 31 | Dead, 73 | — | ||
| 14 | 49 | M | 0 | 0 | Gastrin | 60 | 31 | Dead, 71 | SSA + Inf, Stz + 5FU, Pac + Doxo, Platinum |
Abbreviations: Cap, capecitabine; D, duodenal; Doxo, doxorubicin; Eve, everolimus; F, female; Inf, interferon; M, male; P, pancreatic; SSA, somatostatin receptor analog; Stz, streptozocin; Tmz, temozolomide. The table shows clinical characteristics of patients with secondary hormone secretion. Age was determined as the age at radiological diagnosis. The arrow described the patients with Ki67 values analyzed before and after secondary hormone production.
| Number . | Age . | Gender . | Ki67 . | Biochemistry at Diagnosis . | Hormone Symptoms at Diagnosis . | Secondary Hormone Production . | Time From Diagnosis to Second Hormone . | Time From Second Hormone to Death . | Progression From Second Hormone, mo . | Survival, Months . | Treatment Prior to Conversion . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | M | VIP | VIPoma | Calcitonin | 132 | 20 | Dead, 152 | SSA, Stz + 5FU | ||
| 2 | 75 | F | 12 | PP | 0 | Glucagon, inulin | 90 | 4 | Dead, 94 | Platinum, SSA, Inf, Tmz, Emb, Eve | |
| 3 | 76 | M | 6 | PP | 0 | Insulin, proinsulin | 41 | 18 | Dead, 60 | Tmz, SSA, Stz + 5FU | |
| 4 | 74 | M | 9 | 0 | 0 | Insulin | 18 | 2 | −3 | Dead, 20 | Tmz |
| 5 | 56 | F | Glucagon, proinsulin | Glucagonoma | Insulin | 213 | 20 | Dead, 233 | Strz + 5FU, Tmz, 177Lu-DOTA-octreotate | ||
| 6 | 74 | M | 1 → 40 | 0 | 0 | Insulin, glucagon | 47 | 6 | 0 | Dead, 52 | Stz + 5FU, platinum, |
| 7 | 57 | M | 3 → 1 | 0 | 0 | Glucagon | 12 | 68 | Dead, 81 | ||
| 8 | 56 | F | 10 | PP, proinsulin | 0 | Insulin | 51 | 10 | 0 | Dead, 61 | Stz + Doxo Stz + 5FU, Inf, Im, Tmz |
| 9 | 44 | M | 30 | Gastrin | Gastrinoma | ACTH | 169 | 5 | Dead, 173 | ||
| 10 | 62 | F | 4 | Glucagon, PP, calcitonin, VIP | VIPoma | Insulin | 22 | 13 | 1 | Dead, 46 | Stz + 5FU, Eve |
| 11 | 57 | M | 4 → 17 | 0 | 0 | ACTH | 56 | 19 | 1 | Dead, 76 | Stz + 5FU, Platinum, Tmz + Cap |
| 12 | 44 | M | 3 | VIP | VIPoma | Glucagon, gastrin | 60 | 31 | 0 | Dead, 90 | Stz + 5FU, Tmz |
| 13 | 17 | F | Insulin, pro-insulin, gastrin | Insulinoma | ACTH | 42 | 31 | Dead, 73 | — | ||
| 14 | 49 | M | 0 | 0 | Gastrin | 60 | 31 | Dead, 71 | SSA + Inf, Stz + 5FU, Pac + Doxo, Platinum |
| Number . | Age . | Gender . | Ki67 . | Biochemistry at Diagnosis . | Hormone Symptoms at Diagnosis . | Secondary Hormone Production . | Time From Diagnosis to Second Hormone . | Time From Second Hormone to Death . | Progression From Second Hormone, mo . | Survival, Months . | Treatment Prior to Conversion . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | M | VIP | VIPoma | Calcitonin | 132 | 20 | Dead, 152 | SSA, Stz + 5FU | ||
| 2 | 75 | F | 12 | PP | 0 | Glucagon, inulin | 90 | 4 | Dead, 94 | Platinum, SSA, Inf, Tmz, Emb, Eve | |
| 3 | 76 | M | 6 | PP | 0 | Insulin, proinsulin | 41 | 18 | Dead, 60 | Tmz, SSA, Stz + 5FU | |
| 4 | 74 | M | 9 | 0 | 0 | Insulin | 18 | 2 | −3 | Dead, 20 | Tmz |
| 5 | 56 | F | Glucagon, proinsulin | Glucagonoma | Insulin | 213 | 20 | Dead, 233 | Strz + 5FU, Tmz, 177Lu-DOTA-octreotate | ||
| 6 | 74 | M | 1 → 40 | 0 | 0 | Insulin, glucagon | 47 | 6 | 0 | Dead, 52 | Stz + 5FU, platinum, |
| 7 | 57 | M | 3 → 1 | 0 | 0 | Glucagon | 12 | 68 | Dead, 81 | ||
| 8 | 56 | F | 10 | PP, proinsulin | 0 | Insulin | 51 | 10 | 0 | Dead, 61 | Stz + Doxo Stz + 5FU, Inf, Im, Tmz |
| 9 | 44 | M | 30 | Gastrin | Gastrinoma | ACTH | 169 | 5 | Dead, 173 | ||
| 10 | 62 | F | 4 | Glucagon, PP, calcitonin, VIP | VIPoma | Insulin | 22 | 13 | 1 | Dead, 46 | Stz + 5FU, Eve |
| 11 | 57 | M | 4 → 17 | 0 | 0 | ACTH | 56 | 19 | 1 | Dead, 76 | Stz + 5FU, Platinum, Tmz + Cap |
| 12 | 44 | M | 3 | VIP | VIPoma | Glucagon, gastrin | 60 | 31 | 0 | Dead, 90 | Stz + 5FU, Tmz |
| 13 | 17 | F | Insulin, pro-insulin, gastrin | Insulinoma | ACTH | 42 | 31 | Dead, 73 | — | ||
| 14 | 49 | M | 0 | 0 | Gastrin | 60 | 31 | Dead, 71 | SSA + Inf, Stz + 5FU, Pac + Doxo, Platinum |
Abbreviations: Cap, capecitabine; D, duodenal; Doxo, doxorubicin; Eve, everolimus; F, female; Inf, interferon; M, male; P, pancreatic; SSA, somatostatin receptor analog; Stz, streptozocin; Tmz, temozolomide. The table shows clinical characteristics of patients with secondary hormone secretion. Age was determined as the age at radiological diagnosis. The arrow described the patients with Ki67 values analyzed before and after secondary hormone production.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
